Table 2 Results of meta-analyses in AI-treated BCAC patients (discovery cohort) for the six primary candidate variants

From: Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer

    

OS

DRFS

RFS

rs ID

chr:positiona

ref/effect allele

EAFb (%)

HRc [95% CI]

Pd

HRc [95% CI]

Pd

HRc [95% CI]

Pd

rs3820071

1:15808767

G/A

26.2

1.38 [1.18,1.60]

3.7E-05

1.57 [1.29,1.90]

4.6E-06

1.49 [1.23,1.80]

4.0E-05

rs6685648

1:15825195

T/C

31.6

1.27 [1.10,1.47]

1.3E-03

1.44 [1.20,1.73]

9.0E-05

1.39 [1.16,1.67]

4.0E-04

rs10496860

2:141671250

T/C

11.9

1.32 [1.03,1.70]

2.8E-02

1.86 [1.43,2.44]

4.9E-06

1.73 [1.33,2.24]

4.5E-05

rs3107669

3:119567101

C/A

60.3

1.38 [1.19,1.60]

2.9E-05

1.19 [0.99,1.44]

6.1E-02

1.12 [0.93,1.36]

2.2E-01

rs353298

5:148801379

A/G

41.3

0.78 [0.67,0.92]

2.3E-03

0.63 [0.51,0.78]

1.6E-05

0.66 [0.54,0.81]

7.1E-05

rs353296

5:148801826

G/T

34.3

1.23 [1.06,1.43]

6.1E-03

1.43 [1.18,1.73]

2.7E-04

1.46 [1.21,1.77]

7.4E-05

  1. a Position according to hg19.
  2. b Effect allele frequency (%).
  3. c Per-allele hazard ratio.
  4. d P-values ≤ 1E-04 are marked in bold, p-values between 1E-03 and 1E-04 in italic.
Back to article page